MediciBIO
Biotechnology company developing lipid-based delivery technologies and oligonucleotide therapeutics. Work focuses on ionizable-lipid formulations for mRNA delivery, targeting-lipid approaches for tissue-specific gene delivery, and mutant-selective RNAi oligonucleotide drug development. Also lists platform technology and NCE programs in its pipeline.
Industries
Nr. of Employees
small (1-50)
MediciBIO
Products
Lipid-based delivery platform
Platform technology for formulating and delivering mRNA and oligonucleotide therapeutics using ionizable and targeting lipids.
Mutant-selective oligonucleotide therapeutic programs
Development programs for oligonucleotide therapeutics that selectively target mutant alleles for genetic disease treatment.
MDC-301
H5Nx Avian Influenza Vaccine utilizing capless self-amplifying mRNA combined with proprietary LNP delivery technology.
Mutant-Selective Oligonucleotide Drug
Gene therapy platform and pipeline technology developed by MediciBIO for treating incurable genetic diseases through systematic infrastructure including genetic analysis, OND screening, and efficacy evaluation.
MDC-101
Gene therapy anti-sense oligonucleotide targeting mutant TGFBI R124H mRNA for Avellino corneal dystrophy, administered topically as eye drops.
MDC-004
Organ-targeted LNPs for the spleen and lung using proprietary passive targeting lipids, expanding therapeutic options utilizing organ-specific biodistribution.
Lipid-based delivery platform
Platform technology for formulating and delivering mRNA and oligonucleotide therapeutics using ionizable and targeting lipids.
Mutant-selective oligonucleotide therapeutic programs
Development programs for oligonucleotide therapeutics that selectively target mutant alleles for genetic disease treatment.
MDC-301
H5Nx Avian Influenza Vaccine utilizing capless self-amplifying mRNA combined with proprietary LNP delivery technology.
Mutant-Selective Oligonucleotide Drug
Gene therapy platform and pipeline technology developed by MediciBIO for treating incurable genetic diseases through systematic infrastructure including genetic analysis, OND screening, and efficacy evaluation.
MDC-101
Gene therapy anti-sense oligonucleotide targeting mutant TGFBI R124H mRNA for Avellino corneal dystrophy, administered topically as eye drops.
MDC-004
Organ-targeted LNPs for the spleen and lung using proprietary passive targeting lipids, expanding therapeutic options utilizing organ-specific biodistribution.
Services
R&D and platform work on ionizable-lipid formulations and LNP technologies for nucleic acid delivery.
R&D and platform work on ionizable-lipid formulations and LNP technologies for nucleic acid delivery.
Expertise Areas
- Lipid nanoparticle formulation
- Tissue-targeted gene delivery
- Oligonucleotide/RNAi therapeutic development
- mRNA delivery
Key Technologies
- Lipid nanoparticles (LNP)
- Ionizable lipids
- Targeting lipids for tissue-specific delivery
- RNA interference (RNAi)